Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Optical Activity | ( + ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
InChI
InChIKey=KWGRBVOPPLSCSI-WCBMZHEXSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/pseudoephedrine.htmlCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796
Sources: https://www.drugs.com/pseudoephedrine.html
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796
Pseudoephedrine is a sympathomimetic drug. Pseudoephedrine acts as an adrenomimetic and inhibitor of monoamine transporters. Ephedra sinica, a species of ephedra (ma huang), contains ephedrine and pseudoephedrine. Ephedra has been found to stimulate the nervous system, increase airflow into the lungs and constrict blood vessels. In combination with caffeine, ephedra appears to cause weight loss. Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies.
Originator
Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).
Curator's Comment: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL238 |
5.6 µM [IC50] | ||
Target ID: CHEMBL222 |
1.18 µM [IC50] | ||
Target ID: CHEMBL2095203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954796 |
|||
Target ID: CHEMBL2094118 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10449190 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SUDAFED 24 HOUR Approved Usetemporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure Launch Date7.2429122E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
292 ng/mL |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
PSEUDOEPHEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4346 ng × h/mL |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
PSEUDOEPHEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.3 h |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
PSEUDOEPHEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1500 mg single, oral Overdose |
unknown, 16 years n = 1 Health Status: unknown Age Group: 16 years Sex: F Population Size: 1 Sources: |
Other AEs: Rhabdomyolysis, Creatine kinase increased... Other AEs: Rhabdomyolysis (1 patient) Sources: Creatine kinase increased (1 patient) Blood myoglobin increased (1 patient) |
150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Other AEs: Tension, Dry mouth... Other AEs: Tension (10 patients) Sources: Dry mouth (6 patients) Tachycardia (9 patients) Palpitations (10 patients) Anxiety (13 patients) Insomnia (12 patients) Anorexia (7 patients) Restlessness (10 patients) |
90 mg 1 times / day multiple, oral Overdose Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, 3 years n = 1 Health Status: unhealthy Age Group: 3 years Sex: M Population Size: 1 Sources: |
Disc. AE: Urinary retention... AEs leading to discontinuation/dose reduction: Urinary retention (acute, 1 patient) Sources: |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: sinusitis Age Group: 37 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis, Abdominal pain... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: Abdominal pain (acute, 1 patient) |
720 mg 1 times / day multiple, oral Highest studied dose Dose: 720 mg, 1 times / day Route: oral Route: multiple Dose: 720 mg, 1 times / day Sources: |
unhealthy, 38.8 years n = 38 Health Status: unhealthy Age Group: 38.8 years Sex: M+F Population Size: 38 Sources: |
|
30 mg 3 times / day multiple, oral Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, 44 years n = 1 Health Status: unhealthy Condition: upper airway infection Age Group: 44 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis, Abdominal pain... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: Abdominal pain (acute, 1 patient) |
120 mg 1 times / day multiple, oral Dose: 120 mg, 1 times / day Route: oral Route: multiple Dose: 120 mg, 1 times / day Sources: |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: chronic sinusitis | allergic rhinitis Age Group: 46 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis, Abdominal pain... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: Abdominal pain (acute, 1 patient) |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: chlorpheniramine maleate(2 mg; twice daily, oral) |
unhealthy, 50 years n = 1 Health Status: unhealthy Condition: rhinitis Age Group: 50 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis, Abdominal pain... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: Abdominal pain (acute, 1 patient) |
720 mg single, oral Overdose |
unhealthy, 87 years n = 1 Health Status: unhealthy Age Group: 87 years Sex: M Population Size: 1 Sources: |
Other AEs: Hypertension... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Blood myoglobin increased | 1 patient | 1500 mg single, oral Overdose |
unknown, 16 years n = 1 Health Status: unknown Age Group: 16 years Sex: F Population Size: 1 Sources: |
Creatine kinase increased | 1 patient | 1500 mg single, oral Overdose |
unknown, 16 years n = 1 Health Status: unknown Age Group: 16 years Sex: F Population Size: 1 Sources: |
Rhabdomyolysis | 1 patient | 1500 mg single, oral Overdose |
unknown, 16 years n = 1 Health Status: unknown Age Group: 16 years Sex: F Population Size: 1 Sources: |
Palpitations | 10 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Restlessness | 10 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Tension | 10 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Insomnia | 12 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Anxiety | 13 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Dry mouth | 6 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Anorexia | 7 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Tachycardia | 9 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Urinary retention | acute, 1 patient Disc. AE |
90 mg 1 times / day multiple, oral Overdose Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, 3 years n = 1 Health Status: unhealthy Age Group: 3 years Sex: M Population Size: 1 Sources: |
Ischemic colitis | 1 patient Disc. AE |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: sinusitis Age Group: 37 years Sex: F Population Size: 1 Sources: |
Abdominal pain | acute, 1 patient Disc. AE |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: sinusitis Age Group: 37 years Sex: F Population Size: 1 Sources: |
Ischemic colitis | 1 patient Disc. AE |
30 mg 3 times / day multiple, oral Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, 44 years n = 1 Health Status: unhealthy Condition: upper airway infection Age Group: 44 years Sex: F Population Size: 1 Sources: |
Abdominal pain | acute, 1 patient Disc. AE |
30 mg 3 times / day multiple, oral Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, 44 years n = 1 Health Status: unhealthy Condition: upper airway infection Age Group: 44 years Sex: F Population Size: 1 Sources: |
Ischemic colitis | 1 patient Disc. AE |
120 mg 1 times / day multiple, oral Dose: 120 mg, 1 times / day Route: oral Route: multiple Dose: 120 mg, 1 times / day Sources: |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: chronic sinusitis | allergic rhinitis Age Group: 46 years Sex: F Population Size: 1 Sources: |
Abdominal pain | acute, 1 patient Disc. AE |
120 mg 1 times / day multiple, oral Dose: 120 mg, 1 times / day Route: oral Route: multiple Dose: 120 mg, 1 times / day Sources: |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: chronic sinusitis | allergic rhinitis Age Group: 46 years Sex: F Population Size: 1 Sources: |
Ischemic colitis | 1 patient Disc. AE |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: chlorpheniramine maleate(2 mg; twice daily, oral) |
unhealthy, 50 years n = 1 Health Status: unhealthy Condition: rhinitis Age Group: 50 years Sex: F Population Size: 1 Sources: |
Abdominal pain | acute, 1 patient Disc. AE |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: chlorpheniramine maleate(2 mg; twice daily, oral) |
unhealthy, 50 years n = 1 Health Status: unhealthy Condition: rhinitis Age Group: 50 years Sex: F Population Size: 1 Sources: |
Hypertension | 1 patient | 720 mg single, oral Overdose |
unhealthy, 87 years n = 1 Health Status: unhealthy Age Group: 87 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
A Double-blind crossover trial of pseudoephedrine and triprolidine, alone and in combination, for the treatment of allergenic rhinitis. | 1975 Jan |
|
Dextromethorphan- and pseudoephedrine-induced agitated psychosis and ataxia: case report. | 1999 Mar-Apr |
|
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
Angle closure risk from proprietary medicines. | 2001 Apr |
|
Mass spectrometric quantitation of chiral drugs by the kinetic method. | 2001 Apr 15 |
|
Study on the chiral recognition of the enantiomers of ephedrine derivatives with neutral and sulfated heptakis(2,3-O-diacetyl)-beta-cyclodextrins using capillary electrophoresis, UV, nuclear magnetic resonance spectroscopy and mass spectrometry. | 2001 Apr 20 |
|
Stereocontrolled Mannich reaction with enolizable imines using (S,S)-(+)-pseudoephedrine as chiral auxiliary. Asymmetric synthesis of alpha,beta-disubstituted beta-aminoesters and beta-lactams. | 2001 Dec 28 |
|
Effect of organic cations on the renal tubular secretion of pseudoephedrine in the rat. | 2001 Jan-Feb |
|
Stability indicating HPTLC method for the simultaneous determination of pseudoephedrine and cetirizine in pharmaceutical formulations. | 2001 Jun |
|
Asymmetric synthesis of beta-substituted alpha-methyl-beta-amino esters by Mannich reaction of (S,S)-(+)-pseudoephedrine acetamide derived enolate with imines. | 2001 Mar 8 |
|
[Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3]. | 2001 Mar-Apr |
|
Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine. | 2001 Mar-Apr |
|
Factitious hypertension by pseudoephedrine. | 2001 Mar-Apr |
|
Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. | 2001 May |
|
Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid. | 2001 May |
|
Epinephrine analogues. | 2001 Nov |
|
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. | 2001 Nov |
|
Acute psychosis due to the interaction of legal compounds--ephedra alkaloids in 'vigueur fit' tablets, caffeine in 'red bull' and alcohol. | 2001 Oct |
|
Small-cell carcinoma of the esophagus: report of three cases and review of the literature with emphasis on therapy. | 2001 Sep |
|
Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations. | 2001 Sep |
|
Kinetic spectrophotometric methods for the quantitation of triprolidine in bulk and in drug formulations. | 2001 Sep |
|
Analysis of enantiomers giving partially overlapped peaks by using different treatments of the chromatographic ultraviolet signals: quantification of pseudoephedrine enantiomers. | 2001 Sep 28 |
|
Myocardial infarction temporally related to ephedra--a possible role for the coronary microcirculation. | 2002 |
|
Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE. | 2002 |
|
Generalized dermatitis due to pseudoephedrine. | 2002 Aug |
|
Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. | 2002 Feb 15 |
|
Pseudoephedrine causing mania-like symptoms. | 2002 Feb 22 |
|
Immediate hypersensitivity due to pseudoephedrine. | 2002 Jan |
|
Rapid determination of pseudoephedrine in human plasma by high-performance liquid chromatography. | 2002 Jan 25 |
|
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. | 2002 Jun |
|
Implementation of the Comprehensive Methamphetamine Control Act of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule. | 2002 Mar 28 |
|
[Blood supply of the lips]. | 2002 Oct |
|
[Cutaneous complications following liver transplantation: epidemiologic and clinical study in 86 patients]. | 2002 Oct |
|
Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers. | 2002 Oct |
|
[Toxic dermatitis caused by pseudoephedrine: apropos of a case]. | 2002 Sep |
|
Baboon syndrome due to pseudoephedrine. | 2003 Apr |
|
Sensitive determination of ephedrine and pseudoephedrine by capillary electrophoresis with laser-induced fluorescence detection. | 2003 Apr |
|
Surfing, self-medicating and safety: buying non-prescription and complementary medicines via the internet. | 2003 Apr |
|
Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise. | 2003 Jan |
|
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. | 2003 Jul |
|
[Tobacco: knowledge, reasoning and opinion of high school students in Doubs. Reflections on prevention]. | 2003 Mar |
|
Safety of selegiline with cold medications. | 2003 Mar |
|
Adrenaline given outside the context of life threatening allergic reactions. | 2003 Mar 15 |
|
A comparative study of root canal preparation using FlexMaster and HERO 642 rotary Ni-Ti instruments. | 2003 May |
|
Canine model of nasal congestion and allergic rhinitis. | 2003 May |
|
Press-coating of immediate release powders onto coated controlled release tablets with adhesives. | 2003 May 20 |
Sample Use Guides
SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG
adults and children 12 years and older: a tablet with water every 24 hours
children under 12 years: do not use this product in children under 12 years of age
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21631396
Curator's Comment: Pseudoephedrine inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:52:18 UTC 2023
by
admin
on
Wed Jul 05 22:52:18 UTC 2023
|
Record UNII |
7CUC9DDI9F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR01BA02
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
CFR |
21 CFR 119.1
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
WHO-VATC |
QR01BA52
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
NDF-RT |
N0000175552
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
CFR |
21 CFR 1314.20
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
DEA NO. |
8525
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
WHO-ATC |
R01BA02
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
LIVERTOX |
813
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
NDF-RT |
N0000000209
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
WHO-ATC |
R01BA52
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
||
|
CFR |
21 CFR 1315.13
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
90-82-4
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
7286
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
DTXSID0023537
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
SUB10157MIG
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
DB00852
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
8896
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | RxNorm | ||
|
7CUC9DDI9F
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
1061
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
D054199
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
Pseudoephedrine
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
407885
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
ALTERNATIVE | |||
|
C61914
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
M9294
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | Merck Index | ||
|
202-018-6
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
51209
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
CHEMBL1590
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
100000085477
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
PSEUDOEPHEDRINE
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
3177
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
7028
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
7CUC9DDI9F
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY | |||
|
2326
Created by
admin on Wed Jul 05 22:52:18 UTC 2023 , Edited by admin on Wed Jul 05 22:52:18 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
SUB_CONCEPT->SUBSTANCE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY | |||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||